Seres Therapeutics, Inc. (MCRB): Price and Financial Metrics
MCRB Price/Volume Stats
| Current price | $0.65 | 52-week high | $6.73 |
| Prev. close | $0.63 | 52-week low | $0.60 |
| Day low | $0.65 | Volume | 2,981 |
| Day high | $0.65 | Avg. volume | 4,550,413 |
| 50-day MA | $0.89 | Dividend yield | N/A |
| 200-day MA | $1.97 | Market Cap | 97.43M |
MCRB Stock Price Chart Interactive Chart >
Seres Therapeutics, Inc. (MCRB) Company Bio
Seres Therapeutics is a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company was founded in 2010 and is based in Cambridge, Massachusetts.
Latest MCRB News From Around the Web
Below are the latest news stories about SERES THERAPEUTICS INC that investors may wish to consider to help them evaluate MCRB as an investment opportunity.
Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023CAMBRIDGE, Mass., December 08, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting held from December 9-12, 2023, in San Diego, California, USA. SER-155 is an oral, cultivated live bacteri |
Seres Therapeutics, Inc. (NASDAQ:MCRB) is a favorite amongst institutional investors who own 62%Key Insights Given the large stake in the stock by institutions, Seres Therapeutics' stock price might be vulnerable to... |
Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ETCAMBRIDGE, Mass., November 28, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 3:30 p.m. ET. |
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsFlagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo |
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2023 Earnings Call TranscriptSeres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2023 Earnings Call Transcript November 4, 2023 Operator: Welcome to the Seres Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Kevin Mannix, Head of Investor Relations. Please go ahead. Kevin Mannix: […] |
MCRB Price Returns
| 1-mo | -19.39% |
| 3-mo | -47.15% |
| 6-mo | -54.23% |
| 1-year | -89.62% |
| 3-year | -96.70% |
| 5-year | -90.58% |
| YTD | -53.57% |
| 2023 | -75.00% |
| 2022 | -32.77% |
| 2021 | -66.00% |
| 2020 | 610.14% |
| 2019 | -23.67% |
Continue Researching MCRB
Want to do more research on Seres Therapeutics Inc's stock and its price? Try the links below:Seres Therapeutics Inc (MCRB) Stock Price | Nasdaq
Seres Therapeutics Inc (MCRB) Stock Quote, History and News - Yahoo Finance
Seres Therapeutics Inc (MCRB) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...